Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other Working Capital Changes (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Other Working Capital Changes readings, the most recent being -$112000.0 for Q4 2025.

  • Quarterly Other Working Capital Changes fell 151.85% to -$112000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$430000.0 through Dec 2025, down 814.89% year-over-year, with the annual reading at -$430000.0 for FY2025, 814.89% down from the prior year.
  • Other Working Capital Changes hit -$112000.0 in Q4 2025 for Terns Pharmaceuticals, down from $206000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $2.6 million in Q3 2022 and bottomed at -$2.4 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is -$13000.0, with a median of -$59000.0 recorded in 2021.
  • The largest annual shift saw Other Working Capital Changes tumbled 2383.33% in 2022 before it skyrocketed 1764.18% in 2024.
  • Terns Pharmaceuticals' Other Working Capital Changes stood at -$629000.0 in 2021, then plummeted by 87.6% to -$1.2 million in 2022, then plummeted by 107.63% to -$2.4 million in 2023, then skyrocketed by 108.82% to $216000.0 in 2024, then crashed by 151.85% to -$112000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Other Working Capital Changes are -$112000.0 (Q4 2025), $206000.0 (Q3 2025), and -$412000.0 (Q2 2025).